Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603329 · ClinicalTrials.gov registry record · NA
Increasing Medication Adherence Through Physician Incentives and Messaging
A NA study, sponsored by National Bureau of Economic Research.
- Completed
- Registry status
- NA
- Development phase
- 734
- Enrollment target
NCT01603329: Completed NA study, sponsored by National Bureau of Economic Research.
NCT01603329 is a NA study that has completed, run by National Bureau of Economic Research. The registered enrollment target is 734 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603329, a NA study, has completed, sponsored by National Bureau of Economic Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 734 participants
- Enrollment target
Study Summary
The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.
Primary Outcome
The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
Interventions
- OTHER Increasing Medication Adherence through Physician Incentives and Messaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-03 |
| Phase | NA |
What the finished NCT01603329 record still lists
NCT01603329 is an interventional study that assigns participants to a tested intervention. The registered 734 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Increasing Medication Adherence through Physician Incentives and Messaging is the first listed.
NCT01603329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01603329 about?
NCT01603329 is a clinical study titled "Increasing Medication Adherence Through Physician Incentives and Messaging". The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medicat...
What is the current status of trial NCT01603329?
This trial is currently completed. It is a NA study. The enrollment target is 734 participants. The study started on 2012-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01603329?
The interventions under investigation include: Increasing Medication Adherence through Physician Incentives and Messaging (OTHER).
Who is sponsoring clinical trial NCT01603329?
This trial is sponsored by National Bureau of Economic Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01603329's enrollment target sits among peer trials
734 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia